Fujifilm's factory in Denmark generates USD 430m revenue

Fujifilm Diosynth Biotechnologies, a Japan-based company that produces drugs for other firms, has released its first annual accounting report since it started operating in Denmark. This comes two years after the company bought a medicine factory in the country.

Lars Petersen, CEO of Fujifilm Diosynth Biotechnologies in Denmark | Photo: Fujifilm Diosynth Biotechnologies

Two years after Fujifilm Diosynth Biotechnologies (FDB) spent DKK 6bn (USD 960m) on a medicine factory in Northern Zealand, Denmark, the contract producer has released its first annual accounting report for its Danish operations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs